Exploring the Effects of Omalizumab in Allergic Asthma

Hanania, Nicola A.; Wenzel, Sally E.; Rosén, Karin; Hsieh, Hsin-Ju; Mosesova, Sofia; Choy, David F.; Lal, Preeti; Arron, Joseph R.; Harris, Jeffrey M.; Busse, William W.

doi:10.1164/rccm.201208-1414oc

Cited by 789 publications

(615 citation statements)

References 35 publications

Supporting

Mentioning

543

Contrasting

Unclassified

Order By: Relevance

“…In the EXTRA study conducted by Hanania et al [54] a clinically significant reduction (by 56%) in the frequency of severe asthma exacerbations following the treatment with omalizumab was achieved only in the high peripheral eosinophilia group (≥ 260 EO/µl) as compared to the placebo group. A similar effect was observed for FeNO and serum periostin levels, which are considered biomarkers for eosinophilic airway inflammation.…”

Section: The Impact Of Omalizumab On Eosinophilia In Asthma Patients mentioning

confidence: 94%

The Effect of Omalizumab on Eosinophilic Inflammation of the Respiratory Tract in Patients with Allergic Asthma

Kupryś‐Lipińska¹,

Molińska²,

Kuna³

2016

Advances in Respiratory Medicine

View full text Add to dashboard Cite

Bronchial asthma is characterised by high levels of immunoglobulin E (IgE) and overproduction of pro-inflammatory cytokines, including interleukins IL-4, IL-13 and IL-5 needed for, amongst other things, the production of IgE and the differentiation, maturation, migration and survival of eosinophils. Eosinophils are one of the most important cells in allergic inflammation. Their presence in tissue is linked to the persistence of inflammatory infiltrate, tissue damage and remodelling. Although these cells are very sensitive to corticosteroids, some asthmatic patients do not respond to high doses of these drugs, even when administered systemically. Transbronchial biopsies and bronchoalveolar lavage performed in patients with steroid-resistant asthma have demonstrated higher levels of eosinophils and Th2-type cytokines (IL-4 and IL-5) compared to steroid-sensitive patients. Clinical studies have confirmed that the very effective treatment in these cases is therapy with omalizumab -an anti-IgE monoclonal antibody. The paper discusses the efficacy of omalizumab in reducing eosinophil number in peripheral blood and in the airways of asthmatic patients based on basic, clinical, observational studies and case reports. The significance of omalizumab therapy in asthma control and mechanisms that regulate the effects of omalizumab on eosinophils are evaluated.

show abstract

Section: The Impact Of Omalizumab On Eosinophilia In Asthma Patients mentioning

confidence: 94%

The Effect of Omalizumab on Eosinophilic Inflammation of the Respiratory Tract in Patients with Allergic Asthma

Kupryś‐Lipińska¹,

Molińska²,

Kuna³

2016

Advances in Respiratory Medicine

View full text Add to dashboard Cite

show abstract

“…The cost-effectiveness and cost-utility of pharmacological strategies have been rigorously assessed [29]. However, until recently, the utility of biomarker-assisted asthma diagnosis and management has received little attention [1,6,9]. In airway diseases, biomarkers such as FeNO and blood and sputum eosinophils have been used to provide predictive information to tailor treatments and to differentiate between patients with similar clinical presentations [6,28,29].…”

Section: Discussionmentioning

confidence: 99%

“…FeNO testing has shown its value in identifying individuals who respond to inhaled corticosteroids [7][8] and biologic therapy [9] and has acted as a complement to conventional monitoring of asthma in children and adults in several randomized controlled clinical trials [10][11][12][13][14][15][16]. Moreover, in 2014, the National Institute for Health and Care Excellence (NICE) recommended FeNO testing to help diagnose asthma in adults and children when diagnosis is unclear.…”

Section: Introductionmentioning

confidence: 99%

Cost-effectiveness and Budget Impact of Routine Use of Fractional Exhaled Nitric Oxide Monitoring for the Management of Adult Asthma Patients in Spain

Sabatelli

Seppälä

Sastre

et al. 2017

J Investig Allergol Clin Immunol

View full text Add to dashboard Cite

Objectives: Fractional exhaled nitric oxide (FeNO) is a marker for type 2 airway inflammation. The objective of this study was to evaluate the cost-effectiveness and budget impact of FeNO monitoring for management of adult asthma in Spain. Methods: A cost-effectiveness analysis model was used to evaluate the effect on costs of adding FeNO monitoring to asthma management. Over a 1-year period, the model estimated the incremental cost per quality-adjusted life year and incremental number of exacerbations avoided when FeNO monitoring was added to standard guideline-driven asthma care compared with standard care alone. Univariate and multivariate sensitivity analyses were applied to explore uncertainty in the model. A budget impact model was used to examine the impact of FeNO monitoring on primary care costs across the Spanish health system. Results: The results showed that adding FeNO to standard asthma care saved €62.53 per patient-year in the adult population and improved quality-adjusted life years by 0.026 per patient-year. The budget impact analysis revealed a potential net yearly saving of €129 million if FeNO monitoring had been used in primary care settings in Spain. Conclusions: The present economic model shows that adding FeNO to the treatment algorithm can considerably reduce costs and improve quality of life when used to manage asthma in combination with current treatment guidelines. Key words: Asthma management. Biomarker. Budget impact. Cost-effectiveness. FeNO. Guidelines. Exhaled nitric oxide. ResumenObjetivos: La fracción exhalada del óxido nítrico (FeNO) es un marcador de la inflamación bronquial de tipo Th-2. El objetivo de este estudio ha sido evaluar el coste-efectividad e impacto presupuestario de la monitorización del FeNO en el manejo del asma del adulto en España. Métodos: Se ha utilizado un modelo de análisis de coste-efectividad para evaluar los resultados económicos cuando se utilizó el FeNO en el manejo del asma durante un año. El modelo estimó el incremento de coste por calidad de vida ajustada por año (QALY) y el número de exacerbaciones evitadas cuando se añadió el FeNO a la guía habitual de tratamiento del asma en comparación con la guía habitual. Se aplicó un análisis univariante y multivariante para valorar la posible incertidumbre del modelo. Se utilizó un modelo de impacto presupuestario para evaluar el impacto económico de la introducción de la monitorización con el FeNO en consultas de atención primaria del estado español y teniendo en cuenta el sistema sanitario español. Resultados: Se ha demostrado que el añadir el FeNO al tratamiento habitual del asma ahorra 62,53€ por paciente por año en adultos con asma y mejoró la QALYs en 0,026 por paciente y año. El análisis económico resultó en un ahorro estimado de 129 millones de euros netos por año en consultas de atención primaria. Conclusiones: El modelo económico utilizado ha mostrado que el añadir el FeNO al algoritmo habitual de tratamiento del asma conlleva a un importante ahorro en recursos económicos y un aumento d...

show abstract

“…Стимулированная периостином эозинофиль-ная инфильтрация дыхательных путей вносит значитель-ный вклад в опосредованные эозинофилами воспаление и фиброз [49]. Высокий уровень периостина в сыворотке крови является достаточно надежным предиктором поло-жительного ответа у пациентов на введение омализумаба [50]. Ученые установили, что у пациентов с тяжелой БА при высоком уровне периостина введение в комплексную терапию омализумаба сопровождалось 30% снижением частоты тяжелых обострений, тогда как при низких его уровнях такой эффект наблюдался только у 3% пациентов.…”

Section: периостин как потенциальный маркер эозинофильного воспаленияunclassified

Potential Role of Serum Periostin in the Early Detection of Bronchial Asthma in Children

Sobotyuk¹,

Gaponenko²,

Бочанцев³

et al. 2016

Vopr. sovr. pediatr.

View full text Add to dashboard Cite

АКТУАЛЬНОСТЬНи значительные достижения в диагностике бронхи-альной астмы (БА), ни внедрение в практику современных методов контроля и профилактики бронхиальной обструк-ции так и не привели к снижению заболеваемости, осо-бенно среди детского населения. B наши дни БА -наи-более распространенная хроническая форма патологии дыхательных путей в младшей возрастной группе [1,2].В конце XX -начале XXI века исследователи на экс-периментальных моделях убедительно показали, что Т хел перы второго типа (Th2) играют важнейшую роль в развитии аллергической БА, и с их активацией связаны

show abstract

Exploring the Effects of Omalizumab in Allergic Asthma

Cited by 789 publications

References 35 publications

The Effect of Omalizumab on Eosinophilic Inflammation of the Respiratory Tract in Patients with Allergic Asthma

The Effect of Omalizumab on Eosinophilic Inflammation of the Respiratory Tract in Patients with Allergic Asthma

Cost-effectiveness and Budget Impact of Routine Use of Fractional Exhaled Nitric Oxide Monitoring for the Management of Adult Asthma Patients in Spain

Potential Role of Serum Periostin in the Early Detection of Bronchial Asthma in Children

Contact Info

Product

Resources

About